Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 253

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma

Leonard, John P., Coleman, Morton, Ketas, Jamie C., Chadburn, Amy, Ely, Scott, Furman, Richard R., Wegener, William A., Hansen, Hans J., Ziccardi, Heather, Eschenberg, Michael, Gayko, Urte, Cesano, Alessandra, Goldenberg, David M.·2003·Journal of Clinical Oncology

Abstract

Purpose: This single-center, dose-escalation study examines the safety, efficacy, and pharmacokinetics of epratuzumab (anti-CD22 humanized monoclonal antibody) in patients with recurrent indolent non-Hodgkin’s lymphoma (NHL). Patients and Methods: Patients had indolent NHL and recurrent disease after at least one chemotherapy regimen. Epratuzumab was administered intravenously at 120 to 1,000 mg/m 2 over 30 to 60 minutes weekly for four treatments. Results: Fifty-five patients received epratuzumab and were assessable for safety; 51 patients were assessable for response. Patients were heavily pretreated (50% had at least four prior regimens) and 49% had bulky disease (≥ 5 cm). Epratuzumab was well tolerated, with no dose-limiting toxicity. Circulating B cells transiently decreased without significant effects on T cells or immunoglobulin levels. More than 95% of infusions were completed in approximately 1 hour. Mean serum half-life was 23 days. Across all dose levels and histologies, nine patients (18%; 95% confidence interval, 8% to 31%) achieved objective response, including three complete responses (CRs). All responses were in patients with follicular NHL: 24% of these patients responded, including 43% in the 360 mg/m 2 dose group and 27% in the 480 mg/m 2 dose group. No responses were observed in other indolent histologies. Median duration of objective response was 79.3 weeks (range, 11.1 to 143.3 weeks), with median time to progression for responders of 86.6 weeks by Kaplan-Meier estimate. Conclusion: Epratuzumab was well tolerated at up to 1,000 mg/m 2/wk (for 4 weeks) and had clinical activity. One third of responding patients achieved CR. A 43% objective response rate in follicular NHL patients treated at 360 mg/m 2/wk indicates that this dose should be explored in additional studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2003.01.082

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 253

Metadata

Authors
Leonard, J. P., Coleman, M., Ketas, J. C., Chadburn, A., Ely, S., Furman, R. R., Wegener, W. A., Hansen, H. J., Ziccardi, H., Eschenberg, M., Gayko, U., Cesano, A., & Goldenberg, D. M.
Venue
Journal of Clinical Oncology
Published
2003-08-15
Volume
21
Issue
16
Pages
3051-3059
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2164006259
Cited by
253
References
19
FWCI
13.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2003.01.082
The paper
Leonard, J. P., Coleman, M., Ketas, J. C., Chadburn, A., Ely, S., Furman, R. R., Wegener, W. A., Hansen, H. J., Ziccardi, H., Eschenberg, M., Gayko, U., Cesano, A., & Goldenberg, D. M. (2003). Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.01.082

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.